ALPN - Alpine Immune Sciences Inc
(NaN%)
We couldn't determine Recommendation based on the data we have.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Alpine Immune Sciences Inc (ALPN)
founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Mitchell Gold
Employees - 125
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.